Table 2 Positivity rate for each autoantibody
Total (n = 234) | Patients treated with pirfenidone (n = 142) | Patients never treated with pirfenidone (n = 92) | |
|---|---|---|---|
ANA | 42 (17.9%, n = 234) | 27 (19.0%, n = 142) | 15 (16.3%, n = 92) |
RF | 33 (14.4%, n = 229) | 23 (16.8%, n = 137) | 10 (10.9%, n = 92) |
Cyclic citrullinated peptide antibody | 8 (3.7%, n = 214) | 7 (5.7%, n = 123) | 1(1.1%, n = 91) |
Anti-dsDNA antibody | 3 (2.6%, n = 117) | 3 (4.0%, n = 75) | 0 (0.0%, n = 42) |
Anti-Ro antibody | 8 (6.6%, n = 121) | 4 (5.1%, n = 79) | 4 (9.5%, n = 42) |
Anti-La antibody | 0 (0.0%, n = 121) | 0 (0.0%, n = 79) | 0 (0.0%, n = 42) |
Anti-ribonucleoprotein antibody | 1 (0.9%, n = 110) | 1 (1.4%, n = 71) | 0 (0.0%, n = 39) |
Anti-Smith antibody | 2 (1.8%, n = 110) | 0 (0.0%, n = 71) | 2 (5.1%, n = 39) |
Anti-Scl-70 antibody | 4 (3.7%, n = 109) | 0 (0.0%, n = 70) | 4 (10.3%, n = 39) |
Anti-Jo-1 antibody | 3 (3.0%, n = 99) | 2 (3.3%, n = 60) | 1 (2.6%, n = 39) |
Myeloperoxidase ANCA | 31 (13.4%, n = 231) | 14 (10.1%, n = 139) | 17(18.5%, n = 92) |
Proteinase-3 ANCA | 7 (3.0%, n = 230) | 6 (4.3%, n = 138) | 1(1.1%, n = 92) |
Autoantibody positive | 84 (36.4%) | 49 (34.5%) | 35 (38.0%) |